128 related articles for article (PubMed ID: 37149686)
1. Optimized metrics for orthogonal combinatorial CRISPR screens.
Cetin R; Wegner M; Luwisch L; Saud S; Achmedov T; Süsser S; Vera-Guapi A; Müller K; Matthess Y; Quandt E; Schaubeck S; Beisel CL; Kaulich M
Sci Rep; 2023 May; 13(1):7405. PubMed ID: 37149686
[TBL] [Abstract][Full Text] [Related]
2. Application of CHyMErA Cas9-Cas12a combinatorial genome-editing platform for genetic interaction mapping and gene fragment deletion screening.
Aregger M; Xing K; Gonatopoulos-Pournatzis T
Nat Protoc; 2021 Oct; 16(10):4722-4765. PubMed ID: 34508260
[TBL] [Abstract][Full Text] [Related]
3. RNA-Guided
Ittiprasert W; Chatupheeraphat C; Mann VH; Li W; Miller A; Ogunbayo T; Tran K; Alrefaei YN; Mentink-Kane M; Brindley PJ
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054816
[TBL] [Abstract][Full Text] [Related]
4. Engineered CRISPR-Cas12a variants with increased activities and improved targeting ranges for gene, epigenetic and base editing.
Kleinstiver BP; Sousa AA; Walton RT; Tak YE; Hsu JY; Clement K; Welch MM; Horng JE; Malagon-Lopez J; Scarfò I; Maus MV; Pinello L; Aryee MJ; Joung JK
Nat Biotechnol; 2019 Mar; 37(3):276-282. PubMed ID: 30742127
[TBL] [Abstract][Full Text] [Related]
5. Simple-to-use CRISPR-SpCas9/SaCas9/AsCas12a vector series for genome editing in Saccharomyces cerevisiae.
Okada S; Doi G; Nakagawa S; Kusumoto E; Ito T
G3 (Bethesda); 2021 Dec; 11(12):. PubMed ID: 34739076
[TBL] [Abstract][Full Text] [Related]
6. Comparative optimization of combinatorial CRISPR screens.
Li R; Klingbeil O; Monducci D; Young MJ; Rodriguez DJ; Bayyat Z; Dempster JM; Kesar D; Yang X; Zamanighomi M; Vakoc CR; Ito T; Sellers WR
Nat Commun; 2022 May; 13(1):2469. PubMed ID: 35513429
[TBL] [Abstract][Full Text] [Related]
7. Analysis of combinatorial CRISPR screens with the Orthrus scoring pipeline.
Ward HN; Aregger M; Gonatopoulos-Pournatzis T; Billmann M; Ohsumi TK; Brown KR; Blencowe BJ; Moffat J; Myers CL
Nat Protoc; 2021 Oct; 16(10):4766-4798. PubMed ID: 34508259
[TBL] [Abstract][Full Text] [Related]
8. Optimization of AsCas12a for combinatorial genetic screens in human cells.
DeWeirdt PC; Sanson KR; Sangree AK; Hegde M; Hanna RE; Feeley MN; Griffith AL; Teng T; Borys SM; Strand C; Joung JK; Kleinstiver BP; Pan X; Huang A; Doench JG
Nat Biotechnol; 2021 Jan; 39(1):94-104. PubMed ID: 32661438
[TBL] [Abstract][Full Text] [Related]
9. Engineered Cas12a-Plus nuclease enables gene editing with enhanced activity and specificity.
Huang H; Huang G; Tan Z; Hu Y; Shan L; Zhou J; Zhang X; Ma S; Lv W; Huang T; Liu Y; Wang D; Zhao X; Lin Y; Rong Z
BMC Biol; 2022 Apr; 20(1):91. PubMed ID: 35468792
[TBL] [Abstract][Full Text] [Related]
10. enAsCas12a Enables CRISPR-Directed Evolution to Screen for Functional Drug Resistance Mutations in Sequences Inaccessible to SpCas9.
Neggers JE; Jacquemyn M; Dierckx T; Kleinstiver BP; Thibaut HJ; Daelemans D
Mol Ther; 2021 Jan; 29(1):208-224. PubMed ID: 33002419
[TBL] [Abstract][Full Text] [Related]
11. Optimization of Genomewide CRISPR Screens Using AsCas12a and Multi-Guide Arrays.
Petiwala S; Modi A; Anton T; Murphy E; Kadri S; Hu H; Lu C; Flister MJ; Verduzco D
CRISPR J; 2023 Feb; 6(1):75-82. PubMed ID: 36787117
[TBL] [Abstract][Full Text] [Related]
12. AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines.
Zhang L; Zuris JA; Viswanathan R; Edelstein JN; Turk R; Thommandru B; Rube HT; Glenn SE; Collingwood MA; Bode NM; Beaudoin SF; Lele S; Scott SN; Wasko KM; Sexton S; Borges CM; Schubert MS; Kurgan GL; McNeill MS; Fernandez CA; Myer VE; Morgan RA; Behlke MA; Vakulskas CA
Nat Commun; 2021 Jun; 12(1):3908. PubMed ID: 34162850
[TBL] [Abstract][Full Text] [Related]
13. The Acidaminococcus sp. Cas12a nuclease recognizes GTTV and GCTV as non-canonical PAMs.
Jacobsen T; Liao C; Beisel CL
FEMS Microbiol Lett; 2019 Apr; 366(8):. PubMed ID: 31004485
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas12a-Mediated Genome Editing in
Hao X; Mu T; Sharshar MM; Jia Y; Zhong W; Chen Z; Wen Q; Yang M; Wang C; Xing J
ACS Synth Biol; 2023 Apr; 12(4):1204-1215. PubMed ID: 37017652
[TBL] [Abstract][Full Text] [Related]
15. Genetic interaction mapping and exon-resolution functional genomics with a hybrid Cas9-Cas12a platform.
Gonatopoulos-Pournatzis T; Aregger M; Brown KR; Farhangmehr S; Braunschweig U; Ward HN; Ha KCH; Weiss A; Billmann M; Durbic T; Myers CL; Blencowe BJ; Moffat J
Nat Biotechnol; 2020 May; 38(5):638-648. PubMed ID: 32249828
[TBL] [Abstract][Full Text] [Related]
16. A Single Cas9-VPR Nuclease for Simultaneous Gene Activation, Repression, and Editing in
Dong C; Jiang L; Xu S; Huang L; Cai J; Lian J; Xu Z
ACS Synth Biol; 2020 Sep; 9(9):2252-2257. PubMed ID: 32841560
[TBL] [Abstract][Full Text] [Related]
17. Engineered CRISPR-Cas9 nuclease with expanded targeting space.
Nishimasu H; Shi X; Ishiguro S; Gao L; Hirano S; Okazaki S; Noda T; Abudayyeh OO; Gootenberg JS; Mori H; Oura S; Holmes B; Tanaka M; Seki M; Hirano H; Aburatani H; Ishitani R; Ikawa M; Yachie N; Zhang F; Nureki O
Science; 2018 Sep; 361(6408):1259-1262. PubMed ID: 30166441
[TBL] [Abstract][Full Text] [Related]
18. Benchmarking of SpCas9 variants enables deeper base editor screens of BRCA1 and BCL2.
Sangree AK; Griffith AL; Szegletes ZM; Roy P; DeWeirdt PC; Hegde M; McGee AV; Hanna RE; Doench JG
Nat Commun; 2022 Mar; 13(1):1318. PubMed ID: 35288574
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-AsCas12a Efficiently Corrects a
Torriano S; Baulier E; Garcia Diaz A; Corneo B; Farber DB
CRISPR J; 2022 Jun; 5(3):457-471. PubMed ID: 35686978
[TBL] [Abstract][Full Text] [Related]
20. Cas9, Cpf1 and C2c1/2/3-What's next?
Nakade S; Yamamoto T; Sakuma T
Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
